Loading stock data…
Quest Diagnostics Incorporated (DGX)
$212.64+2.76 (+1.32%)
After Hours$212.64+0.00 (+0.00%)· Last close Jun 29
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Quest Diagnostics Incorporated in the Healthcare sector is trading at $212.64 with a market capitalization of $21.5B. Wall Street consensus targets $223.44 (16 analysts), implying a +5.1% move over the next 12 months. The stock is currently near its 52-week high of $213.50, remaining 12.4% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +5.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.90B↑ | $2.81B↓ | $2.82B↑ | $2.76B↑ | $2.65B |
| Gross Profit | $942.00M↑ | $910.00M↓ | $949.00M↑ | $943.00M↑ | $863.00M |
| Operating Income | $404.00M↑ | $386.00M | $386.00M↓ | $438.00M↑ | $351.00M |
| Net Income | $252.00M↑ | $245.00M | $245.00M↓ | $282.00M↑ | $220.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$21.50B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
21.44
Beta
Defensive asset. Lower volatility than the S&P 500.
0.59
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
1.53%
ROE
Average efficiency. Growth may require heavy reinvestment.
13.90%
Volume
Today's trading volume
781,617
Recent News
How Abbott's Largest Segment Is Preparing for the Next Growth Phase
ABT's Medical Devices unit builds on strong growth with new diabetes, heart rhythm and electrophysiology advances ahead of Q2 2026.
Quest Diagnostics (DGX) Wins Nationwide Haystack MRD Access And Expands Into Psychiatry
Quest Diagnostics (NYSE:DGX) received New York State approval for its Haystack MRD liquid biopsy test, enabling nationwide use for detecting residual or recurrent cancer. The approval follows published research indicating the test’s high sensitivity for minimal residual disease monitoring. Quest Diagnostics also entered a national partnership with Attunio Health to support an AI powered precision psychiatry platform. The partnership is intended to provide scalable laboratory infrastructure...
DGX's Stock Rises on Haystack MRD Test's Approval From NYSDOH
Quest Diagnostics gains NYSDOH approval for Haystack MRD, expanding the cancer test to all 50 states and strengthening its oncology reach.
Is it Apt to Hold Quest Diagnostics Stock in Your Portfolio Now?
DGX gains from Advanced Diagnostics, physician and consumer testing growth, plus AI-driven efficiency efforts, even as debt and policy risks linger.
Is Quest Diagnostics Stock Underperforming the S&P 500?
While Quest Diagnostics has lagged behind the S&P 500 Index over the past year, analysts are moderately optimistic about the stock’s prospects.